Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
MSL Career Options: The transition from Field Medical to Medical Director
Summary
In this episode, Tom Caravela talks with Josh Corriveau about his journey from Medical Science Liaison to Medical Director. Josh shares insights into securing a medical director role and outlines the responsibilities involved. He discusses the essential skills and transferable competencies that facilitate this career advancement, emphasizing the importance of patient care. Josh addresses challenges faced by non-MD candidates and explores opportunities within the field. The conversation extends to the differences between in-house and virtual roles, highlighting the significance of scientific expertise. Josh concludes with advice for field medical professionals navigating the post-COVID landscape, encouraging strategic resourcefulness.
My guest today is Josh Corriveau, the Global Medical Affairs Director at Leo Pharma. We discuss the potential to make a career transition from MSL to Medical Director.
In this episode we discuss:
- The transition from field medical to a medical director
- How Josh got the job and the responsibilities as a medical director
- What skills are mandatory to be considered for these types of roles
- Many Medical Director roles require an MD, would he say it makes it a lot harder if you are a Ph.D. or PharmD?
- His greatest challenges when transitioning into the Medical Director role
- Are all Medical Director roles in-house or can some of these roles be field-based?
- His advice to those in field medical transitioning out of COVID to field visit or hybrid of face to face and virtual interactions
Medical Science Liaison, Medical Director role, career transition, non-MD candidates, post-COVID landscape
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary